have also been implicated in the clinical manifestations of carcinoid tumors [7] The majority of patients with midgut carcinoids develop carcinoid syndrome only in the presence of hepatic metastases and are rarely curable by surgery. Resection of hepatic metastases has been successful in carefully selected patients with severe carcinoid-induced diarrhea and flushing but should only be considered when symptoms are unresponsive to conventional chemotherapeutic agents [8] . Unfortunately, eventual relapse and tachyphylaxis to the drugs is frequently encountered. More recently, suppression with long-acting somatostatin analogue (octreotide) was evaluated in a variety of neuroendocrine tumors including carcinoid. In one recent study of octreotide in 14 patients with biochemical and clinical evidence of carcinoid syndrome, symptoms of flushing, diarrhea, and wheezing were controlled in the majority of patients, but the drug failed to suppress biochemical markers or tumor growth [7] . Despite failure to slow tumor progression, octreotide may provide excellent palliation of symptoms with relatively few adverse effects.
The authors summarize a 10-year surgical experience in 5i patients with midgut carcinoids, 26 (51%) of whom had objective evidence of carcinoid syndrome. Thirty-one patients (61%) had extensive mesenteric fibroplasia or nodal involvement that precluded radical resection and underwent surgical "debulking" or intestinal bypass procedures. Only 6 patients with hepatic involvement were suitable candidates for resection or enucleation. Although survivors were followed for a mean of 2.8 years, the authors did not describe the effects of surgery on the frequency and severity of preoperative symptoms. Since the majority of patients were given postoperative medical therapy, the usefulness of surgery per se cannot be evaluated.
Surgery has a potentially important role in patients with mid-gut carcinoids, but should be viewed as one arm of a multimodality treatment regimen. Curative resection is unusual but should be attempted in all patients with disease limited to the bowel wall and adjacent mesentery. Surgical palliation should always he considered in patients with symptoms of bowel obstruction or ischemia, even in the presence of nodal or hepatic metastases. Similarly, resection of bulky mesenteric, nodal, or hepatic metastases may be useful in carefully-selected patients with symptoms of carcinoid syndrome that prove refractory to medical management or arterial embolization [9] . Postoperative treatment with chemotherapeutic agents and hormonal suppressants may provide useful palliation, but should be withheld until the effects of surgery have been fully evaluated.
